News

Most eyes were fluid-free after 24 weeks with visual acuity increases observed in some.

Rahul Tonk, MD, MBA, gives an overview of the cases he discussed during his portion of a segment on refractive surgery.

Risk stratification, patch graft selection, tube repositioning, and multidisciplinary care all play a role in minimizing erosion and protecting long-term outcomes.

Nicole Bajic, MD, outlines key takeaways from her case study involving Descemet membrane detachment occurring in the setting of focal canaloplasty using the Streamline Surgical System.

Pathik P. Amin, OD, FAAO, details his segment of an educational track session on glaucoma at this year's conference.

Across sessions, speakers emphasized that AI is not a replacement for physician judgment.

Shameema Sikder, MD, details a session she presented with Roomasa Channa, MD, at EnVision Summit 2026.

Improved guidance on preservatives and allergens needed to ensure safety.

Real-world data shows systemic immunomodulators beat local steroids for chronic uveitis, cutting glaucoma, cataract, CME, and ERM risks.

Large study links specific retinal findings to leukemia subtype, predicting remission risk and visual prognosis—prompt eye exams can flag relapse early.

Trial shows AAV8 PDE6A gene therapy doesn’t improve retinitis pigmentosa vision in a year and may cause retinal thinning and VA loss.

Most patients do well on topical therapy, but innovation in IOP-lowering drops remains essential.

ACP says the label “provider” blurs clinical roles, commercializes care, and erodes trust—urging words that protect medical ethics and relationships.

Lab tests show red‑light myopia devices exceed ANSI safety limits in seconds, fueling urgent calls for independent validation before kids use them.

New AAV therapy for retinitis pigmentosa completes Phase I/II dosing, aiming to protect cones and slow vision loss; first readout targets 2027.

Oluwatosin U. Smith, MD, highlights how the foundation provides education, research, and access-to-care for patients and clinicians globally and locally.

Aaron Y. Lee, MD, MSCI, explains how temporal optical coherence tomography modeling may improve longitudinal disease tracking and clinical decision-making at Angiogenesis 2026.

The primary endpoint of the trial is non-inferiority in the mean change from baseline in best-corrected visual acuity (BCVA) at 52 weeks.

The results of a multicenter controlled clinical trial showed that the device resulted in “a significant improvement in visual acuity (VA) from baseline to month 12.

P. Dee G. Stephenson, MD, FACS, shares insights on evolving LAL technology and best practices for managing the ocular surface before and after surgery.

The deal will see MeiraGTx assume development rights to ZipBio’s experimental therapies targeting the complement pathway in geographic atrophy (GA).

The 2025 program built on its evolving reputation as a multispecialty educational forum that successfully integrates ophthalmology and optometry, premium CME content, and a family-friendly format to foster professional growth without sacrificing work–life balance.

EnVision Summit insights spotlight complex glaucoma cases, MIGS pitfalls, and personalized surgery choices—preview the issues driving 2026 debates in Puerto Rico.

China approves ZEISS ARTEVO 750 and 850 ophthalmic microscopes, expanding 3D digital visualization and iOCT-ready workflows for cataract and retinal surgery.

Andrew G. Lee, MD, and Drew Carey, MD, discuss how optic disc cupping after optic neuritis reflects nerve and ganglion cell thinning, not disease type, helping distinguish it from glaucoma.

Metformin, a common diabetes medication, may be associated with less development of intermediate age-related macular degeneration (AMD).

Early first-in-human results suggest Ocumetics’ accommodating IOL shows short-term safety and improved uncorrected distance vision, but data remain limited and preliminary.

Family-friendly format empowers continuing education.